BRAINSTORM CELL THERAPEUTICS INC. (BCLI) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
	10-K	10-K	10-K	10-K	10-K/A	10-K	10-K	10-K
Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Revenue growth								-100.0%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross margin
Selling, general and administrative [+]	9.3	9.4	5.8	5.8	4.0	2.8	3.6	2.6
General and administrative	9.3	9.4	5.8	5.8	4.0	2.8	3.6	2.6
Research and development	15.2	22.3	17.2	8.3	1.0	2.3	4.9	4.8
EBITDA [+]	-24.3	-31.5	-22.8	-14.0	-4.9	-5.0	-8.4	-7.3
EBITDA growth	-22.8%	37.8%	63.7%	183.9%	-1.8%	-40.8%	15.5%	52.3%
EBITDA margin
Depreciation and amortization	0.3	0.2	0.2	0.1	0.1	0.1	0.1	0.1
EBIT [+]	-24.5	-31.7	-23.0	-14.1	-5.0	-5.1	-8.5	-7.4
EBIT growth	-22.6%	37.8%	63.6%	181.3%	-1.7%	-40.5%	15.0%	51.5%
EBIT margin
Other income (expense), net	0.1	-0.1	-0.3	0.1	0.0	0.1	0.0	-1.8
Pre-tax income	-24.5	-31.8	-23.3	-13.9	-5.0	-5.0	-8.5	-9.2
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-24.5	-31.8	-23.3	-13.9	-5.0	-5.0	-8.5	-9.2
Net margin

Basic EPS [+]	($0.68)	($1.07)	($1.06)	($0.70)	($0.26)	($0.27)	($0.46)	($0.68)
Growth	-36.6%	0.4%	52.2%	164.5%	-1.2%	-42.1%	-31.9%	-248.3%
Diluted EPS [+]	($0.68)	($1.07)	($1.06)	($0.70)	($0.26)	($0.27)	($0.46)	($0.68)
Growth	-36.6%	0.4%	52.2%	164.5%	-1.2%	-42.1%	-31.9%	-248.3%

Shares outstanding (basic) [+]	36.2	29.8	21.9	20.0	18.8	18.7	18.4	13.7
Growth	21.2%	36.3%	9.5%	6.5%	0.6%	1.4%	34.7%	27.2%
Shares outstanding (diluted) [+]	36.2	29.8	21.9	20.0	18.8	18.7	18.4	13.7
Growth	21.2%	36.3%	9.5%	6.5%	0.6%	1.4%	34.7%	27.2%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.